3.29Open3.01Pre Close10 Volume20 Open Interest3.00Strike Price3.29KTurnover6347.24%IV1.94%PremiumAug 9, 2024Expiry Date3.17Intrinsic Value100Multiplier-1DDays to Expiry0.12Extrinsic Value100Contract SizeAmericanOptions Type0.9299Delta0.0352Gamma1.86Leverage Ratio-7.3395Theta0.0000Rho1.72Eff Leverage0.0001Vega
Altimmune Stock Discussion
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
Altimmune (Nasdaq: ALT) has published data from a 12-week clinical trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in the Journal of Hepatology. The study focused on metabolic dysfunction-associated steatotic liver disease (MASLD). Key findings include:
- Up to 68.5% relative reduction in liver fat con...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
No comment yet